What Is Lynovex?

A New Potential Solution to CF lung disease symptoms in Oral Form for Exacerbations (Acute use) and Inhaled Form for Long Term Use Unique Multi-Action Therapy

Unique Multi-Action Therapy: Antibiotic, Antibiofilm, Antibiotic Potentiating, Mucolytic

A Mutation-Agnostic Treatment with activity irrespective of CFTR genotype

Lynovex® Latest

Patients at the centre of rare disease therapy development

Three Posters on New Lynovex Preclinical and Clinical Data

Novabiotics To Present New Data On Their Novel Cystic Fibrosis Drugs At The European Cf Society’S Annual Conference

Novabiotics Presenting New Data At European Cystic Fibrosis Conference

Grant Support For Lynovex